(NASDAQ: KRSA) Korsana Biosciences's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 13.33%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 66.02%.
Korsana Biosciences's earnings in 2026 is -$6,707,000.On average, 7 Wall Street analysts forecast KRSA's earnings for 2026 to be -$2,787,208, with the lowest KRSA earnings forecast at -$4,817,107, and the highest KRSA earnings forecast at -$1,193,744. On average, 7 Wall Street analysts forecast KRSA's earnings for 2027 to be -$2,327,432, with the lowest KRSA earnings forecast at -$2,595,339, and the highest KRSA earnings forecast at -$1,924,034.
In 2028, KRSA is forecast to generate -$2,012,311 in earnings, with the lowest earnings forecast at -$2,130,013 and the highest earnings forecast at -$1,924,034.